In a U.S. and Swiss study, nearly all patients with cancer developed good immune response to the COVID-19 mRNA vaccines three to four weeks after receiving their second dose, but the fact that a small group of the patients ...
Jul 1, 2021
0
2
Researchers report in the journal Cancer Cell an experimental therapy that in laboratory tests on human cells and mouse models stops aggressive, treatment-resistant and deadly brain cancers called glioblastoma and high-grade ...
May 9, 2016
0
17
Obesity is the second-leading preventable cause of cancer and represents one of the greatest threats to global human health. But it has not been clear exactly how whole-body metabolism affects tumor formation. In particular, ...
Apr 9, 2018
0
6
Among people with advanced basal cell carcinomas who see their skin cancers shrink or disappear in response to a common drug therapy, about 20 percent will relapse within months as the cancer cells become resistant to the ...
Mar 10, 2015
0
7
Macrophages are a type of white blood cell that are among the body's first line of defense against infection. In addition to killing harmful microorganisms, macrophages typically can initiate a response against tumors. However, ...
Sep 26, 2023
0
49
A patient has become the first to receive a new 'resistance-busting' experimental skin cancer drug with the launch of a phase I clinical trial.
May 5, 2015
0
14
The Telomere and Telomerase Group at the Spanish National Cancer Research Centre (CNIO) has shown that it is possible to block the growth of human and murine glioblastoma in mouse models by blocking the TRF1 protein, an essential ...
Nov 14, 2017
0
4
Scientists at St. Jude Children's Research Hospital and the University of Würzburg in Germany have identified a protein interaction that is a hallmark of an aggressive subtype of medulloblastoma and that may provide a new ...
Jan 11, 2016
0
425
Greater knowledge of the mechanisms that contribute to the survival of tumour cells is key to vanquishing them. The study published today in the journal Cancer Cell, headed by Angel R. Nebreda, ICREA researcher at the Institute ...
May 24, 2018
0
10
A genetic misfire called the 3q26.2 amplicon can cause real havoc. In fact, it is among the most frequent chromosomal aberrations seen in many cancers, including ovarian and breast cancers.
Dec 8, 2014
0
0
